Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity.
Cancer management and research
Yang Z, Pan Q, Zhang D, Chen J, Qiu Y, Chen X, Zheng F, Lin F.
Publication Overview
Key findings, Countstar context, and access to the original paper.
2019
Cancer Research
Immunology
No items found.
Key Finding
In addition, silibinin could effectively reduce cisplatin and/or toxal-induced hepatotoxicity by protecting DNA from damage and restoring the potential of cell proliferation in cisplatin and/or toxal-treated LO2 cells. The findings suggest that silibinin could restore the sensitivity of cisplatin and taxol in drug-resistant human ovarian cancer cells and reduce durg-induced hepatotoxicity in cell level.
Countstar Connection
In this work, Countstar (model not specified) measured cell numbers during growth assessment in the study's cell samples during growth assessment for the immune-cell research.
